{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:47:53Z","timestamp":1787593673573,"version":"build-2736575974"},"reference-count":89,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81630090"],"award-info":[{"award-number":["81630090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81672019, 81822045 and 81661128041"],"award-info":[{"award-number":["81672019, 81822045 and 81661128041"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81703571"],"award-info":[{"award-number":["81703571"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Megaprojects of China for Major Infectious Diseases","award":["2018ZX10301403"],"award-info":[{"award-number":["2018ZX10301403"]}]},{"name":"U.S. NIH","award":["AI127346 and DK119937"],"award-info":[{"award-number":["AI127346 and DK119937"]}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"crossref","award":["201706100104"],"award-info":[{"award-number":["201706100104"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81701998"],"award-info":[{"award-number":["81701998"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1008082","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T13:27:42Z","timestamp":1575552462000},"page":"e1008082","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies"],"prefix":"10.1371","volume":"15","author":[{"given":"Wenwen","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2255-0391","authenticated-orcid":true,"given":"Lu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0350-5560","authenticated-orcid":true,"given":"Lishan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8283-7135","authenticated-orcid":true,"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"issue":"9180","key":"ppat.1008082.ref001","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(98)12262-6","article-title":"Transmission of antiretroviral-drug-resistant HIV-1 variants","volume":"354","author":"S Yerly","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"ppat.1008082.ref002","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcv.2004.02.009","article-title":"Antiviral drugs in current clinical use","volume":"30","author":"E De Clercq","year":"2004","journal-title":"J Clin Virol"},{"issue":"6442","key":"ppat.1008082.ref003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/365113a0","article-title":"HIV-1 inhibition by a peptide","volume":"365","author":"S Jiang","year":"1993","journal-title":"Nature"},{"issue":"3","key":"ppat.1008082.ref004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"T Matthews","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"9369","key":"ppat.1008082.ref005","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(03)13323-5","article-title":"Enfuvirtide, a new drug for HIV infection","volume":"361","author":"CV Fletcher","year":"2003","journal-title":"Lancet"},{"issue":"22","key":"ppat.1008082.ref006","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMp030043","article-title":"HIV infection\u2014a new drug and new costs","volume":"348","author":"R Steinbrook","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"ppat.1008082.ref007","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/00002030-200303280-00007","article-title":"A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy","volume":"17","author":"JP Lalezari","year":"2003","journal-title":"AIDS"},{"issue":"2","key":"ppat.1008082.ref008","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1128\/AAC.50.2.667-673.2006","article-title":"Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings","volume":"50","author":"H Stocker","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"ppat.1008082.ref009","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/088922202760072294","article-title":"The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults","volume":"18","author":"JM Kilby","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"ppat.1008082.ref010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1067\/mcp.2002.125945","article-title":"Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition","volume":"72","author":"X Zhang","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"ppat.1008082.ref011","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"FM Veronese","year":"2005","journal-title":"Drug Discov Today"},{"issue":"7","key":"ppat.1008082.ref012","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","article-title":"Pegylation: a novel process for modifying pharmacokinetics","volume":"40","author":"JM Harris","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"ppat.1008082.ref013","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s11095-013-1067-7","article-title":"The immunogenicity of polyethylene glycol: facts and fiction","volume":"30","author":"H Schellekens","year":"2013","journal-title":"Pharm Res"},{"issue":"11","key":"ppat.1008082.ref014","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"RP Garay","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"ppat.1008082.ref015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"AW Richter","year":"1983","journal-title":"Int Arch Allergy Appl Immunol"},{"issue":"2","key":"ppat.1008082.ref016","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/07388551.2013.834293","article-title":"Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics","volume":"35","author":"T Rath","year":"2015","journal-title":"Crit Rev Biotechnol"},{"issue":"5","key":"ppat.1008082.ref017","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1015396825274","article-title":"Pharmaceutical strategies utilizing recombinant human serum albumin","volume":"19","author":"VT Chuang","year":"2002","journal-title":"Pharm Res"},{"issue":"7","key":"ppat.1008082.ref018","doi-asserted-by":"crossref","first-page":"e102566","DOI":"10.1371\/journal.pone.0102566","article-title":"Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice","volume":"9","author":"JT Sockolosky","year":"2014","journal-title":"PLoS One"},{"issue":"5456","key":"ppat.1008082.ref019","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1126\/science.287.5456.1279","article-title":"Convergent solutions to binding at a protein-protein interface","volume":"287","author":"WL DeLano","year":"2000","journal-title":"Science"},{"key":"ppat.1008082.ref020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1742-4690-11-40","article-title":"Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK","volume":"11","author":"H Chong","year":"2014","journal-title":"Retrovirology"},{"issue":"3","key":"ppat.1008082.ref021","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1096\/fj.12-222547","article-title":"Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1","volume":"27","author":"H Chong","year":"2013","journal-title":"FASEB J"},{"issue":"10","key":"ppat.1008082.ref022","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1745-7254.2005.00163.x","article-title":"Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro","volume":"26","author":"SJ Dai","year":"2005","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"ppat.1008082.ref023","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/QAD.0000000000001073","article-title":"Development of potent and long-acting HIV-1 fusion inhibitors","volume":"30","author":"H Chong","year":"2016","journal-title":"AIDS"},{"issue":"11","key":"ppat.1008082.ref024","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00288-17","article-title":"A Lipopeptide HIV-1\/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity","volume":"91","author":"H Chong","year":"2017","journal-title":"J Virol"},{"issue":"16","key":"ppat.1008082.ref025","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00775-18","article-title":"Design of Novel HIV-1\/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models","volume":"92","author":"H Chong","year":"2018","journal-title":"J Virol"},{"issue":"6","key":"ppat.1008082.ref026","article-title":"A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life","volume":"24","author":"S Su","year":"2019","journal-title":"Molecules"},{"issue":"31","key":"ppat.1008082.ref027","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1073\/pnas.0701478104","article-title":"Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus","volume":"104","author":"JJ Dwyer","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ppat.1008082.ref028","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11904-012-0125-9","article-title":"Renal dysfunction in the setting of HIV\/AIDS","volume":"9","author":"JM Miro","year":"2012","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"4","key":"ppat.1008082.ref029","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.acthis.2018.03.006","article-title":"Histomorphological changes in the pancreas and kidney and histopathological changes in the liver in male Wistar rats on antiretroviral therapy and melatonin treatment","volume":"120","author":"D Truter","year":"2018","journal-title":"Acta Histochem"},{"key":"ppat.1008082.ref030","first-page":"1","article-title":"Assessment of the effect of antiretroviral therapy on renal and liver functions among HIV-infected patients: a retrospective study","volume":"9","author":"BH Wondifraw","year":"2017","journal-title":"HIV AIDS (Auckl)"},{"issue":"3","key":"ppat.1008082.ref031","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cmi.2012.7","article-title":"HIV-1 immunopathogenesis in humanized mouse models","volume":"9","author":"L Zhang","year":"2012","journal-title":"Cell Mol Immunol"},{"issue":"20","key":"ppat.1008082.ref032","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00937-17","article-title":"Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein","volume":"91","author":"A Bardhi","year":"2017","journal-title":"J Virol"},{"key":"ppat.1008082.ref033","first-page":"e65","article-title":"An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene","volume":"5","author":"Z Sun","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"ppat.1008082.ref034","doi-asserted-by":"crossref","first-page":"10844","DOI":"10.1038\/ncomms10844","article-title":"Elimination of HIV-1-infected cells by broadly neutralizing antibodies","volume":"7","author":"T Bruel","year":"2016","journal-title":"Nat Commun"},{"issue":"3","key":"ppat.1008082.ref035","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"TC Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"ppat.1008082.ref036","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"TC Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"5","key":"ppat.1008082.ref037","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth","volume":"45","author":"J Huang","year":"2016","journal-title":"Immunity"},{"issue":"21","key":"ppat.1008082.ref038","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"RS Rudicell","year":"2014","journal-title":"J Virol"},{"issue":"7424","key":"ppat.1008082.ref039","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"J Huang","year":"2012","journal-title":"Nature"},{"issue":"2","key":"ppat.1008082.ref040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.virol.2005.06.008","article-title":"Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4","volume":"339","author":"Q Zhao","year":"2005","journal-title":"Virology"},{"issue":"12","key":"ppat.1008082.ref041","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1074\/jbc.M411141200","article-title":"Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120","volume":"280","author":"S Liu","year":"2005","journal-title":"J Biol Chem"},{"key":"ppat.1008082.ref042","doi-asserted-by":"crossref","first-page":"13028","DOI":"10.1038\/srep13028","article-title":"Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy","volume":"5","author":"X Zhu","year":"2015","journal-title":"Sci Rep"},{"issue":"2","key":"ppat.1008082.ref043","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00003088-200544020-00003","article-title":"Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide","volume":"44","author":"IH Patel","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"ppat.1008082.ref044","doi-asserted-by":"crossref","first-page":"12567","DOI":"10.1074\/jbc.M412770200","article-title":"Steric accessibility of the HIV-1 gp41 N-trimer region","volume":"280","author":"AE Hamburger","year":"2005","journal-title":"J Biol Chem"},{"issue":"12","key":"ppat.1008082.ref045","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1110\/ps.038273.108","article-title":"Characterization of the steric defense of the HIV-1 gp41 N-trimer region","volume":"17","author":"DM Eckert","year":"2008","journal-title":"Protein Sci"},{"issue":"1","key":"ppat.1008082.ref046","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/ADR-180078","article-title":"Pharmacokinetics in Rat of P8, a Peptide Drug Candidate for the Treatment of Alzheimer's Disease: Stability and Delivery to the Brain","volume":"2","author":"NN Dewji","year":"2018","journal-title":"J Alzheimers Dis Rep"},{"issue":"13","key":"ppat.1008082.ref047","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.7150\/ijms.21875","article-title":"Peptides as Therapeutic Agents for Dengue Virus","volume":"14","author":"MF Chew","year":"2017","journal-title":"Int J Med Sci"},{"key":"ppat.1008082.ref048","doi-asserted-by":"crossref","first-page":"15672","DOI":"10.1038\/ncomms15672","article-title":"A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses","volume":"8","author":"Y Yu","year":"2017","journal-title":"Nat Commun"},{"issue":"24","key":"ppat.1008082.ref049","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1128\/JVI.01678-06","article-title":"Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells","volume":"80","author":"JC Jones","year":"2006","journal-title":"J Virol"},{"issue":"4","key":"ppat.1008082.ref050","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijantimicag.2003.07.022","article-title":"Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus","volume":"23","author":"MV Albiol","year":"2004","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"ppat.1008082.ref051","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/3293","article-title":"Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry","volume":"4","author":"JM Kilby","year":"1998","journal-title":"Nat Med"},{"issue":"Pt 1","key":"ppat.1008082.ref052","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mce.2015.07.003","article-title":"Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists","volume":"418","author":"B Finan","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"ppat.1008082.ref053","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/eje.0.1460863","article-title":"The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects","volume":"146","author":"H Hui","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"Pt A","key":"ppat.1008082.ref054","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"JS Suk","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"ppat.1008082.ref055","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Q Yang","year":"2015","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"1\u20132","key":"ppat.1008082.ref056","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijpharm.2008.06.004","article-title":"Particle size-dependent triggering of accelerated blood clearance phenomenon","volume":"362","author":"H Koide","year":"2008","journal-title":"Int J Pharm"},{"issue":"1","key":"ppat.1008082.ref057","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-3659(02)00462-5","article-title":"Accelerated clearance of PEGylated liposomes in rats after repeated injections","volume":"88","author":"T Ishida","year":"2003","journal-title":"J Control Release"},{"issue":"3","key":"ppat.1008082.ref058","first-page":"996","article-title":"Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose","volume":"293","author":"P Laverman","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"ppat.1008082.ref059","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/0192623315591171","article-title":"PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development","volume":"43","author":"IA Ivens","year":"2015","journal-title":"Toxicol Pathol"},{"issue":"41","key":"ppat.1008082.ref060","doi-asserted-by":"crossref","first-page":"14323","DOI":"10.1021\/ja504390x","article-title":"Therapeutic protein-polymer conjugates: advancing beyond PEGylation","volume":"136","author":"EM Pelegri-O'Day","year":"2014","journal-title":"J Am Chem Soc"},{"issue":"6","key":"ppat.1008082.ref061","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.trsl.2006.09.007","article-title":"Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys","volume":"149","author":"MA Young","year":"2007","journal-title":"Transl Res"},{"issue":"2","key":"ppat.1008082.ref062","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/toxsci\/42.2.152","article-title":"Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins","volume":"42","author":"A Bendele","year":"1998","journal-title":"Toxicol Sci"},{"issue":"1","key":"ppat.1008082.ref063","article-title":"Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors","volume":"91","author":"S Su","year":"2017","journal-title":"J Virol"},{"issue":"2","key":"ppat.1008082.ref064","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.0300-9475.2004.01376.x","article-title":"Immunoglobulin levels amongst persons with and without human immunodeficiency virus type 1 infection in Uganda and Norway","volume":"59","author":"ES Lugada","year":"2004","journal-title":"Scand J Immunol"},{"issue":"8","key":"ppat.1008082.ref065","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM198308253090803","article-title":"Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome","volume":"309","author":"HC Lane","year":"1983","journal-title":"N Engl J Med"},{"issue":"6049","key":"ppat.1008082.ref066","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"JF Scheid","year":"2011","journal-title":"Science"},{"issue":"47","key":"ppat.1008082.ref067","doi-asserted-by":"crossref","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"H Mouquet","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5950","key":"ppat.1008082.ref068","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"LM Walker","year":"2009","journal-title":"Science"},{"issue":"5","key":"ppat.1008082.ref069","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"A Halper-Stromberg","year":"2014","journal-title":"Cell"},{"issue":"9","key":"ppat.1008082.ref070","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrmicro974","article-title":"Passive antibody therapy for infectious diseases","volume":"2","author":"A Casadevall","year":"2004","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"ppat.1008082.ref071","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/S2352-3018(15)00177-0","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial","volume":"2","author":"JP Lalezari","year":"2015","journal-title":"Lancet HIV"},{"issue":"7","key":"ppat.1008082.ref072","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00426-12","article-title":"In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068","volume":"56","author":"B Nowicka-Sans","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ppat.1008082.ref073","article-title":"Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV","author":"Y Zhang","year":"2018","journal-title":"J Virol"},{"issue":"42","key":"ppat.1008082.ref074","doi-asserted-by":"crossref","first-page":"16332","DOI":"10.1073\/pnas.0807335105","article-title":"Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains","volume":"105","author":"Y He","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"ppat.1008082.ref075","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1074\/jbc.M411141200","article-title":"Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120","volume":"280","author":"S Liu","year":"2005","journal-title":"J Biol Chem"},{"key":"ppat.1008082.ref076","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1742-4690-9-104","article-title":"A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains","volume":"9","author":"L Lu","year":"2012","journal-title":"Retrovirology"},{"issue":"6631","key":"ppat.1008082.ref077","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/387426a0","article-title":"Atomic structure of the ectodomain from HIV-1 gp41","volume":"387","author":"W Weissenhorn","year":"1997","journal-title":"Nature"},{"issue":"6","key":"ppat.1008082.ref078","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1084\/jem.174.6.1557","article-title":"Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120\/gp41","volume":"174","author":"SB Jiang","year":"1991","journal-title":"J Exp Med"},{"issue":"13","key":"ppat.1008082.ref079","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1128\/JVI.00791-15","article-title":"Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy","volume":"89","author":"Q Wang","year":"2015","journal-title":"J Virol"},{"issue":"14","key":"ppat.1008082.ref080","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1089\/08892220260235353","article-title":"XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41","volume":"18","author":"Q Zhao","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"11","key":"ppat.1008082.ref081","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1093\/jac\/dkt230","article-title":"An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides","volume":"68","author":"P Tong","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"17","key":"ppat.1008082.ref082","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1074\/jbc.M800200200","article-title":"Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor","volume":"283","author":"Y He","year":"2008","journal-title":"J Biol Chem"},{"issue":"44","key":"ppat.1008082.ref083","doi-asserted-by":"crossref","first-page":"31888","DOI":"10.1074\/jbc.M113.494609","article-title":"Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry","volume":"288","author":"M Kim","year":"2013","journal-title":"J Biol Chem"},{"issue":"5","key":"ppat.1008082.ref084","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.bbamem.2013.12.022","article-title":"ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer","volume":"1838","author":"F Yu","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"ppat.1008082.ref085","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/bdd.2510110603","article-title":"MODFIT: a pharmacokinetics computer program","volume":"11","author":"GD Allen","year":"1990","journal-title":"Biopharm Drug Dispos"},{"issue":"9","key":"ppat.1008082.ref086","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.1074\/jbc.M111.317883","article-title":"Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide","volume":"287","author":"X Yao","year":"2012","journal-title":"J Biol Chem"},{"issue":"7","key":"ppat.1008082.ref087","doi-asserted-by":"crossref","first-page":"e1004291","DOI":"10.1371\/journal.ppat.1004291","article-title":"Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice","volume":"10","author":"G Li","year":"2014","journal-title":"PLoS Pathog"},{"issue":"1","key":"ppat.1008082.ref088","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1172\/JCI90745","article-title":"Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs","volume":"127","author":"L Cheng","year":"2017","journal-title":"J Clin Invest"},{"issue":"10","key":"ppat.1008082.ref089","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1172\/JCI105917","article-title":"Catabolism of human gammaG-immunoglobulins of different heavy chain subclasses. I. Catabolism of gammaG-myeloma proteins in man","volume":"47","author":"HL Spiegelberg","year":"1968","journal-title":"J Clin Invest"}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1008082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T03:36:30Z","timestamp":1576294590000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1008082"}},"subtitle":[],"editor":[{"given":"Katie J","family":"Doores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":89,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1008082","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]}}}